Table 2.
The percentages of CD69+ CD19+ cells in myocardium, spleen, and blood in AMI and control mice
| Group | n | CD19+ CD69+ (%) | ||
|---|---|---|---|---|
| Myocardium | Spleen | Blood | ||
| AMI 3d | 8 | 10.62 ± 1.62*# | 6.05 ± 0.73*# | 5.32 ± 0.73*# |
| Sham 3d | 6 | 3.72 ± 0.51 | 3.62 ± 0.36 | 2.29 ± 0.43 |
| AMI 5d | 8 | 22.71 ± 3.43* | 12.40 ± 2.07* | 6.82 ± 0.77* |
| Sham 5d | 6 | 3.75 ± 0.29 | 3.80 ± 0.40 | 2.76 ± 0.39 |
| AMI 1W | 8 | 7.62 ± 1.74*# | 4.02 ± 0.58*# | 3.60 ± 0.73# |
| Sham 1W | 6 | 3.53 ± 0.65 | 3.71 ± 0.56 | 2.84 ± 0.55 |
| AMI 2W | 8 | 4.45 ± 0.75# | 4.13 ± 0.82# | 3.10 ± 0.58# |
| Sham 2W | 6 | 3.40 ± 0.44 | 3.58 ± 0.59 | 2.58 ± 0.67 |
*P < 0.05, the activated B cell ratio of AMI group was compared with the corresponding subgroups of the Sham group
#P < 0.05, the activated B cell ratio of other subgroups of the AMI group was compared with AMI 5 days subgroups. Data are represented by mean ± standard deviation